Gilead Sciences, Inc. $GILD Position Lowered by Stone Summit Wealth LLC

Stone Summit Wealth LLC decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 11.3% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 27,189 shares of the biopharmaceutical company’s stock after selling 3,480 shares during the quarter. Stone Summit Wealth LLC’s holdings in Gilead Sciences were worth $4,053,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Strategic Investment Solutions Inc. IL acquired a new position in Gilead Sciences in the 4th quarter worth about $25,000. Persistent Asset Partners Ltd acquired a new stake in shares of Gilead Sciences during the second quarter valued at about $25,000. Kimelman & Baird LLC bought a new stake in shares of Gilead Sciences during the second quarter worth about $25,000. Wealth Preservation Advisors LLC grew its holdings in shares of Gilead Sciences by 60.0% during the fourth quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 81 shares during the last quarter. Finally, Wiser Advisor Group LLC acquired a new position in shares of Gilead Sciences in the second quarter valued at approximately $30,000. Institutional investors own 83.67% of the company’s stock.

Key Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Analysts remain bullish on Gilead, highlighting the company among attractive healthcare stocks. The positive view reflects Gilead’s HIV, liver-disease and oncology franchises, as well as its longer-term growth prospects. Analysts Are Bullish on These Healthcare Stocks: BioNTech SE (BNTX), Gilead Sciences (GILD)
• Positive Sentiment: Bank of America said survey results support a favorable long-term outlook for Yeztugo, Gilead’s HIV-prevention drug. Strong adoption potential could provide an additional growth driver for the company’s HIV portfolio. Gilead Sciences’ Yeztugo Survey Supports Long-Term Growth Outlook, BofA Says
• Positive Sentiment: Erste Group Bank modestly raised its FY2027 EPS forecast for Gilead to $9.90 from $9.88, signaling confidence in the company’s future profitability. Erste Group Bank Raises Gilead Sciences EPS Estimate
• Neutral Sentiment: Recent comparisons with GRAIL and Vertex Pharmaceuticals provide valuation and operating-context analysis but do not identify a specific new catalyst for GILD. Contrasting GRAIL and Gilead Sciences Gilead Sciences versus Vertex Pharmaceuticals
• Negative Sentiment: Gilead’s upcoming third-quarter earnings report is expected to show a double-digit year-over-year EPS decline. That forecast is weighing on sentiment despite optimism about the company’s longer-term pipeline and product growth. Earnings Preview: What to Expect From Gilead Sciences’ Report

Insider Activity

In other news, Director Anthony Welters sold 18,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $148.62, for a total value of $2,675,160.00. Following the transaction, the director owned 12,894 shares in the company, valued at approximately $1,916,306.28. The trade was a 58.26% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $137.64, for a total transaction of $3,853,920.00. Following the sale, the insider owned 118,234 shares of the company’s stock, valued at approximately $16,273,727.76. This trade represents a 19.15% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 105,000 shares of company stock worth $14,940,540. 0.30% of the stock is owned by insiders.

Gilead Sciences Trading Down 1.7%

Shares of GILD stock opened at $147.92 on Wednesday. The stock has a market cap of $183.41 billion, a price-to-earnings ratio of -55.40 and a beta of 0.31. The stock has a 50-day moving average of $145.77 and a 200-day moving average of $136.87. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. Gilead Sciences, Inc. has a 1-year low of $114.02 and a 1-year high of $157.29.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) EPS for the quarter, topping analysts’ consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. The company had revenue of $7.80 billion for the quarter, compared to analyst estimates of $7.40 billion. During the same period in the previous year, the firm earned $2.01 earnings per share. The firm’s quarterly revenue was up 10.6% on a year-over-year basis. On average, equities research analysts forecast that Gilead Sciences, Inc. will post -0.47 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, September 29th. Shareholders of record on Tuesday, September 15th were issued a dividend of $0.82 per share. The ex-dividend date was Tuesday, September 15th. This represents a $3.28 annualized dividend and a yield of 2.2%. Gilead Sciences’s dividend payout ratio (DPR) is presently -122.85%.

Wall Street Analyst Weigh In

GILD has been the subject of a number of research reports. Weiss Ratings upgraded shares of Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, September 14th. Royal Bank Of Canada boosted their target price on shares of Gilead Sciences from $123.00 to $126.00 and gave the stock a “sector perform” rating in a report on Thursday, October 8th. Leerink Partners cut shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $146.00 to $127.00 in a research report on Tuesday, July 21st. Needham & Company LLC restated a “buy” rating and issued a $170.00 price target on shares of Gilead Sciences in a research report on Wednesday, August 5th. Finally, Zacks Research downgraded shares of Gilead Sciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 29th. Twenty-three equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $159.33.

Gilead Sciences Profile

Gilead Sciences, Inc (NASDAQ: GILD) is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. Its research and commercial activities focus primarily on virology, including HIV, hepatitis B and hepatitis C, as well as oncology, inflammation and other areas of significant unmet medical need.

Gilead’s portfolio includes HIV treatments such as Biktarvy, Descovy, Genvoya and Sunlenca; hepatitis therapies including Epclusa, Harvoni and Vemlidy; and Veklury (remdesivir), an antiviral used to treat COVID-19 in certain patients.